NCT07097935View on ClinicalTrials.gov

Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

July 10, 2027

Study Completion Date

July 10, 2028

Conditions
Advanced Clear Cell Renal Cell Carcinoma
Interventions
DRUG

HS-10516 + Lenvatinib

Administered orally.

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY